Intravitreal Cidofovir Injection for Refractory End-Stage Glaucoma and Vision Loss in Silicone Oil-Filled Eyes Following Retinal Reattachment Surgery in Dogs: Four Cases.

Intravitreal cidofovir offers feasible pain control and IOP reduction in refractory glaucoma when enucleation declined.

This retrospective case series describes the use of intravitreal cidofovir injection for palliative management of refractory end-stage glaucoma in four dogs with silicone oil-filled eyes following retinal reattachment surgery. Cidofovir provides pharmacologic ciliary body ablation, reducing aqueous humor production. All treated eyes demonstrated marked intraocular pressure (IOP) reduction within 14-28 days post-injection (final IOP: 3-7 mmHg), with adequate pain control maintained throughout follow-up (median 306.5 days). Ocular comfort and cosmetic appearance were satisfactory in all cases per owner assessment. Adverse effects included moderate to severe post-injection ocular discharge, conjunctival hyperemia, and aqueous flare in all cases, managed with topical medications. One eye developed progressive phthisis bulbi at long-term follow-up; remaining eyes maintained acceptable globe integrity. The authors conclude that intravitreal cidofovir injection represents a feasible palliative alternative to enucleation for dogs with refractory glaucoma in silicone oil-filled eyes, though they recommend further studies to characterize long-term safety and efficacy.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.